Hans Christoph Tanner
Swiss (born 1951), has been a Board Member of Cosmo Pharmaceuticals NV since 2006. Since 2006 until May 2016 he was Chief Financial Officer and Head of Investor Relations of Cosmo Pharmaceuticals, from May 2016 he has been Head of Transactions Office and Head of Investor Relations. Chris Tanner has a diploma as an economist and a PhD in economics from the University of St.Gallen. He joined UBS in 1977 and following a management trainee program worked in various foreign assignments. In 1985, he became a member of the global credit committee and from 1987 to 1992 was the head of corporate banking in Asia, Australia and Africa as well as Southern Europe. In 1992 he became head of corporate finance and capital markets at UBS in Zurich. In 1998, one year after UBS’s merger with SBC, he left to become a partner of Dr. Ernst Müller-Möhl, cofounded the “20 Minuten” group of newspapers and founded A&A Active Investor, a listed investment company. From 2002 – 2006 he was a corporate finance adviser and participated in numerous fund raisings amongst other for the private placement of Cosmo Holding S.p.A. He is a board member and head of the audit committee of DKSH AG (SIX: DKSH), a market expansion company, a board member and head of the Compensation Committee of Private Equity Holding AG, (SIX: PEH) a private equity investment company, Joimax GmbH, a medtech company, and Qvanteq AG, a medtech start-up company. None of the companies that Chris Tanner is a major shareholder of has any business activities with the Company.